Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis
P @ Work
1 other identifier
observational
401
1 country
32
Brief Summary
The purpose of this study is to describe the impact of treatment with adalimumab on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2015
Longer than P75 for all trials
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 21, 2015
CompletedFirst Submitted
Initial submission to the registry
February 9, 2015
CompletedFirst Posted
Study publicly available on registry
February 12, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 6, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 6, 2020
CompletedFebruary 11, 2021
February 1, 2021
5.1 years
February 9, 2015
February 9, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Change in Rheumatoid Arthritis-Work Instability Scale (RA-WIS)
This is patient-reported assessment on the impact of adalimumab on the work status of RA patients.
From Month 0 to Month 6
Change in Financial Loss
This is patient reported assessment of financial burden of RA.
From Month 0 to Month 6
Secondary Outcomes (16)
Change in Rheumatoid Arthritis-Work Instability (RA-WIS)
From Month 0 to Month 12, 18 and 24
Change in the Financial Loss
From Month 0 to Month 12, 18 and 24
Change in patient pain
From Month 0 to Month 24
Change in Tender Joint Count (TJC)
From Month 0 to Month 24
Change in Disease Activity Score (DAS) 28
From Month 0 to Month 24
- +11 more secondary outcomes
Study Arms (1)
Adalimumab subjects
Subjects starting Adalimumab treatment at time of enrollment.
Eligibility Criteria
This is a Multi-Center Canadian Observational Study that will enroll rheumatoid arthristis (RA) subjects for whom the treating physician has decided to treat with adalimumab.
You may qualify if:
- Subjects with moderate to severe RA for whom the physician has decided to initiate treatment with adalimumab
- Adult male or female ≥ 18 years old that has been newly prescribed adalimumab therapy according to the local product label and are with PROGRESS
- Subjects should be evaluated for tuberculosis (TB) exposure/risk factors for active and latent TB
- Subject is able to give written patient authorization and is willing to comply with the requirements of this study protocol.
You may not qualify if:
- Subject cannot or will not sign a patient authorization
- Subject with a known hypersensitivity to Adalimumab, or any of its components
- Presence of any condition that, in the opinion of the treating physician, prohibits the subject from participating in the study or obscures the assessment of the treatment of RA
- Subjects currently participating in an investigational clinical trial
- Subjects treated with \>1 prior biologic disease-modifying antirheumatic drugs (DMARDs) for RA. Any prior treatment with adalimumab is prohibited
- Subjects previously treated with targeted synthetic disease modifying agent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (32)
Pont, Cranbrook, BC, CA /ID# 134511
Cranbrook, British Columbia, V1C 2R7, Canada
Drs. M & W Teo Inc. /ID# 148641
Penticton, British Columbia, V2A 4Z1, Canada
The Arthritis Research Center /ID# 147466
Vancouver, British Columbia, V5Z 1L7, Canada
Kur, Vancouver, CA /ID# 135371
Vancouver, British Columbia, V5Z 3Y1, Canada
Manitoba Clinic /ID# 134830
Winnipeg, Manitoba, R3A 1M3, Canada
Nexus Clinical Research /ID# 135411
St. John's, Newfoundland and Labrador, A1B 5E8, Canada
St. Clare's Mercy Hospital /ID# 136737
St. John's, Newfoundland and Labrador, A1C 5B8, Canada
Dr. Juris Lazovskis Inc. /ID# 134510
Sydney, Nova Scotia, B1S 3N1, Canada
Waterside Clinique /ID# 134190
Barrie, Ontario, L4M 6L2, Canada
Drs Nalin and Vandana Ahluwali /ID# 136485
Brampton, Ontario, L6T 0G1, Canada
Dr. Sanjay Dixit Medicine Professional Corporation /ID# 136486
Burlington, Ontario, L7L 0B7, Canada
Dr. Chrisotomor Kouroukis & Dr /ID# 151189
Dundas, Ontario, L9H 1B7, Canada
Adachi Medicine Prof. Corp /ID# 152538
Hamilton, Ontario, L8N 1Y2, Canada
West Mountain Medical Center /ID# 134832
Hamilton, Ontario, L9C 5N2, Canada
Dr. Martin M.S. Lee Med Prof C /ID# 138333
Mississauga, Ontario, L5A 1W4, Canada
Brandusa Florica Med Prof Corp /ID# 134829
Mississauga, Ontario, L5A 3V8, Canada
Montgomery, Mississauga, CA /ID# 136943
Mississauga, Ontario, L5A 3V8, Canada
Credit Valley Rheumatology /ID# 134834
Mississauga, Ontario, L5M 2V8, Canada
Rajwinder S. Dhillon Medicine /ID# 147756
Niagara Falls, Ontario, L2E 6A6, Canada
Capital North Therapeutics Res /ID# 134835
Ottawa, Ontario, K1Y 4G2, Canada
Setty, Owen Sound, CA /ID# 134189
Owen Sound, Ontario, N4K 1S4, Canada
The Medical Centre /ID# 134833
Peterborough, Ontario, K9J 7B3, Canada
Involved Medicine /ID# 163880
Toronto, Ontario, M3H 5S4, Canada
Dr. Samuel K Silverberg /ID# 136496
Toronto, Ontario, M9V 4B8, Canada
Institut de Rhum. de Montreal /ID# 135289
Montreal, Quebec, H2L 1S6, Canada
Jewish General Hospital /ID# 204168
Montreal, Quebec, H3T 1E2, Canada
PSS Medical Inc. /ID# 134193
Montreal, Quebec, H3T 1Y3, Canada
Clinique de Rhumatologie de Montréal /ID# 162186
Montreal, Quebec, H4N 1C6, Canada
Ctr. de Rheum de l'est du QC /ID# 135410
Rimouski, Quebec, G5L 8W1, Canada
Rheum Disease Ctr of Montreal /ID# 135372
Westmount, Quebec, H3Z 2Z3, Canada
Dr. Latha Naik /ID# 135813
Saskatoon, Saskatchewan, S7K 3H3, Canada
Chuq - Chul /Id# 137054
Québec, G1V 4G2, Canada
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AbbVie Inc.
AbbVie
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 9, 2015
First Posted
February 12, 2015
Study Start
January 21, 2015
Primary Completion
March 6, 2020
Study Completion
March 6, 2020
Last Updated
February 11, 2021
Record last verified: 2021-02